Tetracycline

• Description:

  Tetracycline is a broad-spectrum antibiotic with oral activity. Tetracycline exhibits activity against a wide range of bacteria including gram-positive, gram-negative bacteria, chlamydiae, mycoplasmas and rickettsiae. Tetracycline can be used for the research of infections[1].

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H350, H360

• Target:

  Antibiotic; Bacterial

• Related Pathways:

  Anti-infection

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Cancer

• Purity:

  98.0

• Solubility:

  DMSO : 116.67 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL (ultrasonic)

• Smiles:

  O=C(C(C1=O)=C(O)[C@@H](N(C)C)[C@]2([H])C[C@]3([H])[C@](C)(O)C4=C(C(C3=C(O)[C@@]21O)=O)C(O)=CC=C4)N

• Molecular Formula:

  C22H24N2O8

• Molecular Weight:

  444.43

• Precautions:

  H302, H350, H360

• References & Citations:

  [1]Chopra I, et al. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology ofbacterial resistance. Microbiol Mol Biol Rev. 2001 Jun;65 (2) :232-60.|[2]Bowdre JH, et al. Antibiotic efficacy against Vibrio vulnificus in the mouse: superiority of tetracycline. J Pharmacol Exp Ther. 1983 Jun;225 (3) :595-8.|[3]Forloni G, et al. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001 Jan 5;487 (3) :404-7.|[4]Dugray A, et al. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette. Leukemia. 2001 Oct;15 (10) :1658-62.|[5]Ziółkowski H, et al. Comparative pharmacokinetics of chlortetracycline, tetracycline, minocycline, and tigecycline in broiler chickens. Poult Sci. 2020 Oct;99 (10) :4750-4757.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  Tetracycline

• Citation 01:

  Adv Healthc Mater. 2025 Oct 21:e02853.|Adv Sci (Weinh) . 2020 Jul 21;7 (17) :2001374.|AMB Express. 2024 Dec 24;14 (1) :141.|Anim Dis. 2021;1 (1) :26.|Antimicrob Agents Chemother. 2021 Feb 17;65 (3) :e01921-20.|bioRxiv. 2023 Feb 5.|Cancer Res. 2023 Apr 4;83 (7) :1048-1061.|Cell Res. 2023 Jan;33 (1) :30-45.|Chem Eng J. 2023 Oct 15, 474, 145978.|Chemosphere. 2019 Jun:225:378-387.|Chemosphere. 2023 Dec:344:140353.|Diagn Micr Infec Dis. 2020 Nov;98 (3) :115129.|Drug Des Devel Ther. 2022 Nov 15:16:3929-3946.|EBioMedicine. 2022 Apr;78:103943.|Exp Cell Res. 2020 Aug 15;393 (2) :112090.|Future Microbiol. 2025 Oct 13:1-10.|J Clin Invest. 2023 Apr 17;133 (8) :e159941.|J Extracell Vesicles. 2024 Jul;13 (7) :e12468.|Microb Biotechnol. 2021 Nov;14 (6) :2538-2551.|Microbiol Spectr. 2022 Feb 23;10 (1) :e0099121.|Microbiol Spectr. 2025 Aug 29:e0059025.|Microbiol Spectr. 2025 Oct 15:e0122125.|Microorganisms. 2024 Mar 13;12 (3) :575.|Microorganisms. 2025 Apr 18;13 (4) :938.|mSystems. 2023 Dec 21;8 (6) :e0102623.|Nat Commun. 2022 Mar 2;13 (1) :1116.|Patent. US20200101105A1.|Pathogens. 2024 Nov 15;13 (11) :1003.|PLoS Pathog. 2024 Dec 31;20 (12) :e1012783.|Research (Wash D C) . 2024 Jul 16:7:0415.|Research Square Preprint. 2020 Jun.|Saudi Pharm J. 2021 Jun;29 (6) :566-575.|Sci Rep. 2022 Aug 25;12 (1) :14502.|Toxics. 2023 Jul 13;11 (7) :611.|Vet Microbiol. 2024 May:292:110046.|Vet Res Commun. 2024 Dec;48 (6) :3859-3872.|Water Res. 2023 Jul 15:240:120110.|Water. 2025 Jun 6.|Adv Healthc Mater. 2025 Oct 21:e02853.|Aquat Toxicol. 2025 Feb 9:280:107284.|Biochem Biophys Res Commun. 2024 Oct 29:739:150914.|bioRxiv. 2024 Jan 18.|Cell Res. 2020 Dec;30 (12) :1063-1077.|iScience. 2025 Nov 17.|J Med Virol. 2025 May;97 (5) :e70356.|Katedra farmakologie a toxikologie. 2020 Jul.|Mater Today. 2025 Sep 12.|MBio. 2019 Aug 27;10 (4) . pii: e01949-19.|Nat Commun. 2025 Oct 27;16 (1) :9450.|SSRN. 2025 Jan 2.|SSRN. 2025 Jul 29.

• CAS Number:

  [60-54-8]